LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in Enterococcus faecium

Author:

Axell-House Dierdre B.123,Simar Shelby R.4,Panesso Diana1235,Rincon Sandra5,Miller William R.123ORCID,Khan Ayesha6ORCID,Pemberton Orville A.7,Valdez Lizbet12,Nguyen April H.8,Hood Kara S.12,Rydell Kirsten12,DeTranaltes Andrea M.12,Jones Mary N.12,Atterstrom Rachel12,Reyes Jinnethe5ORCID,Sahasrabhojane Pranoti V.9,Suleyman Geehan10,Zervos Marcus10,Shelburne Samuel A.911ORCID,Singh Kavindra V.123ORCID,Shamoo Yousif7ORCID,Hanson Blake M.4ORCID,Tran Truc T.123ORCID,Arias Cesar A.123ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA

2. Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA

3. Department of Medicine, Weill Cornell Medical College, New York, New York, USA

4. Center for Infectious Diseases, University of Texas Health Science Center, School of Public Health, Houston, Texas, USA

5. Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogotá, Colombia

6. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

7. Department of Biosciences, Rice University, Houston, Texas, USA

8. McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA

9. Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

10. Department of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA

11. Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract

ABSTRACT Daptomycin (DAP) is often used as a first-line therapy to treat vancomycin-resistant Enterococcus faecium infections, but emergence of DAP non-susceptibility threatens the effectiveness of this antibiotic. Moreover, current methods to determine DAP minimum inhibitory concentrations (MICs) have poor reproducibility and accuracy. In enterococci, DAP resistance is mediated by the LiaFSR cell membrane stress response system, and deletion of liaR encoding the response regulator results in hypersusceptibility to DAP and antimicrobial peptides. The main genes regulated by LiaR are a cluster of three genes, designated liaXYZ . In Enterococcus faecalis , LiaX is surface-exposed with a C-terminus that functions as a negative regulator of cell membrane remodeling and an N-terminal domain that is released to the extracellular medium where it binds DAP. Thus, in E. faecalis , LiaX functions as a sentinel molecule recognizing DAP and controlling the cell membrane response, but less is known about LiaX in E. faecium . Here, we found that liaX is essential in E. faecium with an activated LiaFSR system. Unlike E. faecalis , E. faecium LiaX is not detected in the extracellular milieu and does not appear to alter phospholipid architecture. We further postulated that LiaX could be used as a surrogate marker for cell envelope activation and non-susceptibility to DAP. For this purpose, we developed and optimized a LiaX enzyme-linked immunosorbent assay (ELISA). We then assessed 86 clinical E. faecium bloodstream isolates for DAP MICs and used whole genome sequencing to assess for substitutions in LiaX. All DAP-resistant clinical strains of E. faecium exhibited elevated LiaX levels. Strikingly, 73% of DAP-susceptible isolates by standard MIC determination also had elevated LiaX ELISAs compared to a well-characterized DAP-susceptible strain. Phylogenetic analyses of predicted amino acid substitutions showed 12 different variants of LiaX without a specific association with DAP MIC or LiaX ELISA values. Our findings also suggest that many E. faecium isolates that test DAP susceptible by standard MIC determination are likely to have an activated cell stress response that may predispose to DAP failure. As LiaX appears to be essential for the cell envelope response to DAP, its detection could prove useful to improve the accuracy of susceptibility testing by anticipating therapeutic failure.

Funder

HHS | National Institutes of Health

Houston Methodist Clinical Scholars Award

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3